First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings

Matteo Ferro; Giuseppe Lucarelli; Felice Crocetto; Pasquale Dolce; Antonio Verde; Evelina La Civita; Silvia Zappavigna; Ottavio de Cobelli; Giuseppe Di Lorenzo; Bianca Arianna Facchini; Luca Scafuri; Livia Onofrio; Angelo Porreca; Gian Maria Busetto; Guru Sonpavde; Michele Caraglia; Michele Klain; Daniela Terracciano; Sabino De Placido; Carlo Buonerba

doi:10.1016/j.critrevonc.2020.103198

First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings

Matteo Ferro, Giuseppe Lucarelli, Felice Crocetto, Pasquale Dolce, Antonio Verde, Evelina La Civita, Silvia Zappavigna, Ottavio de Cobelli, Giuseppe Di Lorenzo, Bianca Arianna Facchini, Luca Scafuri, Livia Onofrio, Angelo Porreca, Gian Maria Busetto, Guru Sonpavde, Michele Caraglia, Michele Klain, Daniela Terracciano, Sabino De Placido, Carlo Buonerba

Research output: Contribution to journal › Article › peer-review

Abstract

Although both docetaxel and androgen-receptor-axis-targeted (ARAT) agents have yielded survival improvements in combination with androgen deprivation therapy (ADT) compared to ADT alone in metastatic castration-sensitive prostate cancer (mCSPC) patients, the optimal therapeutic choice remains to be established. We analyzed estimates of the hazard ratios for death (OS-HRs) in patients treated in the first-line setting enrolled in the GETUG-AFU15, CHAARTED, STAMPEDE, LATITUDE, ENZAMET, and TITAN trials. Overall, men with mCSPC receiving ADT with vs. without either an ARAT agent or docetaxel as first-line systemic therapy showed a pooled OS-HR of 0.69 (95 % CI: 0.61-0.78), with significant heterogeneity (p = 0.045, I2 = 52.5 %). Network meta-analysis showed an OS-HR in patients receiving an ARAT agent vs. docetaxel of 0.78 (95 %CI: 0.67-0.91). In conclusion, the evidence analysed indicates that an ARAT agent may provide improved OS outcomes compared to docetaxel. Prospective randomized trials are warranted.

Original language	English
Pages (from-to)	103198
Journal	Critical Reviews in Oncology/Hematology
Volume	157
DOIs	https://doi.org/10.1016/j.critrevonc.2020.103198
Publication status	Published - Jan 2021

Keywords

Androgen Antagonists
Castration
Docetaxel/therapeutic use
Humans
Male
Prospective Studies
Prostatic Neoplasms/drug therapy
Prostatic Neoplasms, Castration-Resistant/drug therapy

Access to Document

10.1016/j.critrevonc.2020.103198

Cite this

Ferro, M., Lucarelli, G., Crocetto, F., Dolce, P., Verde, A., La Civita, E., Zappavigna, S., de Cobelli, O., Di Lorenzo, G., Facchini, B. A., Scafuri, L., Onofrio, L., Porreca, A., Busetto, G. M., Sonpavde, G., Caraglia, M., Klain, M., Terracciano, D., De Placido, S., & Buonerba, C. (2021). First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings. Critical Reviews in Oncology/Hematology, 157, 103198. https://doi.org/10.1016/j.critrevonc.2020.103198

Ferro, M, Lucarelli, G, Crocetto, F, Dolce, P, Verde, A, La Civita, E, Zappavigna, S, de Cobelli, O , Di Lorenzo, G, Facchini, BA, Scafuri, L, Onofrio, L, Porreca, A, Busetto, GM, Sonpavde, G, Caraglia, M, Klain, M, Terracciano, D, De Placido, S & Buonerba, C 2021, 'First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings', Critical Reviews in Oncology/Hematology, vol. 157, pp. 103198. https://doi.org/10.1016/j.critrevonc.2020.103198

@article{3824132380854ebdb56b9f13932aba1a,

title = "First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings",

abstract = "Although both docetaxel and androgen-receptor-axis-targeted (ARAT) agents have yielded survival improvements in combination with androgen deprivation therapy (ADT) compared to ADT alone in metastatic castration-sensitive prostate cancer (mCSPC) patients, the optimal therapeutic choice remains to be established. We analyzed estimates of the hazard ratios for death (OS-HRs) in patients treated in the first-line setting enrolled in the GETUG-AFU15, CHAARTED, STAMPEDE, LATITUDE, ENZAMET, and TITAN trials. Overall, men with mCSPC receiving ADT with vs. without either an ARAT agent or docetaxel as first-line systemic therapy showed a pooled OS-HR of 0.69 (95 % CI: 0.61-0.78), with significant heterogeneity (p = 0.045, I2 = 52.5 %). Network meta-analysis showed an OS-HR in patients receiving an ARAT agent vs. docetaxel of 0.78 (95 %CI: 0.67-0.91). In conclusion, the evidence analysed indicates that an ARAT agent may provide improved OS outcomes compared to docetaxel. Prospective randomized trials are warranted.",

keywords = "Androgen Antagonists, Castration, Docetaxel/therapeutic use, Humans, Male, Prospective Studies, Prostatic Neoplasms/drug therapy, Prostatic Neoplasms, Castration-Resistant/drug therapy",

author = "Matteo Ferro and Giuseppe Lucarelli and Felice Crocetto and Pasquale Dolce and Antonio Verde and {La Civita}, Evelina and Silvia Zappavigna and {de Cobelli}, Ottavio and {Di Lorenzo}, Giuseppe and Facchini, {Bianca Arianna} and Luca Scafuri and Livia Onofrio and Angelo Porreca and Busetto, {Gian Maria} and Guru Sonpavde and Michele Caraglia and Michele Klain and Daniela Terracciano and {De Placido}, Sabino and Carlo Buonerba",

year = "2021",

month = jan,

doi = "10.1016/j.critrevonc.2020.103198",

language = "English",

volume = "157",

pages = "103198",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - First-line systemic therapy for metastatic castration-sensitive prostate cancer

T2 - An updated systematic review with novel findings

AU - Ferro, Matteo

AU - Lucarelli, Giuseppe

AU - Crocetto, Felice

AU - Dolce, Pasquale

AU - Verde, Antonio

AU - La Civita, Evelina

AU - Zappavigna, Silvia

AU - de Cobelli, Ottavio

AU - Di Lorenzo, Giuseppe

AU - Facchini, Bianca Arianna

AU - Scafuri, Luca

AU - Onofrio, Livia

AU - Porreca, Angelo

AU - Busetto, Gian Maria

AU - Sonpavde, Guru

AU - Caraglia, Michele

AU - Klain, Michele

AU - Terracciano, Daniela

AU - De Placido, Sabino

AU - Buonerba, Carlo

PY - 2021/1

Y1 - 2021/1

N2 - Although both docetaxel and androgen-receptor-axis-targeted (ARAT) agents have yielded survival improvements in combination with androgen deprivation therapy (ADT) compared to ADT alone in metastatic castration-sensitive prostate cancer (mCSPC) patients, the optimal therapeutic choice remains to be established. We analyzed estimates of the hazard ratios for death (OS-HRs) in patients treated in the first-line setting enrolled in the GETUG-AFU15, CHAARTED, STAMPEDE, LATITUDE, ENZAMET, and TITAN trials. Overall, men with mCSPC receiving ADT with vs. without either an ARAT agent or docetaxel as first-line systemic therapy showed a pooled OS-HR of 0.69 (95 % CI: 0.61-0.78), with significant heterogeneity (p = 0.045, I2 = 52.5 %). Network meta-analysis showed an OS-HR in patients receiving an ARAT agent vs. docetaxel of 0.78 (95 %CI: 0.67-0.91). In conclusion, the evidence analysed indicates that an ARAT agent may provide improved OS outcomes compared to docetaxel. Prospective randomized trials are warranted.

AB - Although both docetaxel and androgen-receptor-axis-targeted (ARAT) agents have yielded survival improvements in combination with androgen deprivation therapy (ADT) compared to ADT alone in metastatic castration-sensitive prostate cancer (mCSPC) patients, the optimal therapeutic choice remains to be established. We analyzed estimates of the hazard ratios for death (OS-HRs) in patients treated in the first-line setting enrolled in the GETUG-AFU15, CHAARTED, STAMPEDE, LATITUDE, ENZAMET, and TITAN trials. Overall, men with mCSPC receiving ADT with vs. without either an ARAT agent or docetaxel as first-line systemic therapy showed a pooled OS-HR of 0.69 (95 % CI: 0.61-0.78), with significant heterogeneity (p = 0.045, I2 = 52.5 %). Network meta-analysis showed an OS-HR in patients receiving an ARAT agent vs. docetaxel of 0.78 (95 %CI: 0.67-0.91). In conclusion, the evidence analysed indicates that an ARAT agent may provide improved OS outcomes compared to docetaxel. Prospective randomized trials are warranted.

KW - Androgen Antagonists

KW - Castration

KW - Docetaxel/therapeutic use

KW - Humans

KW - Male

KW - Prospective Studies

KW - Prostatic Neoplasms/drug therapy

KW - Prostatic Neoplasms, Castration-Resistant/drug therapy

U2 - 10.1016/j.critrevonc.2020.103198

DO - 10.1016/j.critrevonc.2020.103198

M3 - Article

C2 - 33316417

SN - 1040-8428

VL - 157

SP - 103198

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

ER -

First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings

Abstract

Keywords

Access to Document

Fingerprint

Cite this